

Technology Advisory Interests Register

Topic: Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Ed Wilson	HST Committee Member	Financial	I gave advice and feedback to the manufacturer of givinostat on their decision model during development. I am therefore conflicted for this appraisal.	23/06/2025	It was agreed that Ed's declaration would prevent them from participating in discussions on this appraisal.
Emtiyaz Chowdhury	HST Committee Member	Non-Financial Professional Interests	I am employed by Parexel. Parexel provides services to manufacturers of both technologies. I have not been directly involved in any work related to either technology.	30/06/2025	It was agreed that Ed's declaration would not prevent them from participating in discussions on this appraisal.
Dr Anne-Marie Childs	Clinical Expert	Direct - financial	Attended one clinical advisory board meeting with fellow clinicians in the UK in March 2024 for italfarmaco.	04/07/2024	It was agreed that Dr Childs' declaration would not prevent them from providing expert advice to the committee.
Dr Tracey Willis	Clinical Expert	Direct - financial	Medical advisory board; 18 th April 2024. Market Access Advisory board; 20 th June 2024.	01/07/2024	It was agreed that Dr Willis' declaration would not prevent them from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Tracey Willis	Clinical Expert	Direct - non-financial	PI on the Italfarmaco phase 3 trial; double-blind placebo-controlled trial (Givostat).	01/07/2024	It was agreed that Dr Willis' declaration would not prevent them from providing expert advice to the committee.